JP2022547948A5 - - Google Patents
Info
- Publication number
- JP2022547948A5 JP2022547948A5 JP2022515624A JP2022515624A JP2022547948A5 JP 2022547948 A5 JP2022547948 A5 JP 2022547948A5 JP 2022515624 A JP2022515624 A JP 2022515624A JP 2022515624 A JP2022515624 A JP 2022515624A JP 2022547948 A5 JP2022547948 A5 JP 2022547948A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cgrp
- composition according
- igfr
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897686P | 2019-09-09 | 2019-09-09 | |
| US62/897,686 | 2019-09-09 | ||
| US201962946122P | 2019-12-10 | 2019-12-10 | |
| US62/946,122 | 2019-12-10 | ||
| PCT/US2020/070511 WO2021051130A1 (en) | 2019-09-09 | 2020-09-09 | Combination therapy for the treatment of migraines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547948A JP2022547948A (ja) | 2022-11-16 |
| JP2022547948A5 true JP2022547948A5 (cg-RX-API-DMAC10.html) | 2023-09-27 |
Family
ID=74866081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515624A Pending JP2022547948A (ja) | 2019-09-09 | 2020-09-09 | 片頭痛の処置のための併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12324827B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4027984A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022547948A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020346186A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3153776A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021051130A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023133562A1 (en) * | 2022-01-07 | 2023-07-13 | Endosome Therapeutics, Inc. | Methods of treating pain |
| EP4780481A1 (en) * | 2023-09-18 | 2026-07-29 | Ohio State Innovation Foundation | Treating gliomas with calcitonin gene-related peptide antagonist |
| KR102775899B1 (ko) * | 2023-12-19 | 2025-02-28 | 한림대학교 산학협력단 | 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2101865T3 (es) | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
| US5965520A (en) | 1996-07-25 | 1999-10-12 | Research Corporation Technologies | Therapeutic treatment of rheumatoid arthritis and polymyalgia rheumatica |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| CA2349290A1 (en) | 1998-11-19 | 2000-06-02 | Elan Corporation, Plc | Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
| DE60217066T4 (de) | 2001-02-09 | 2010-07-01 | Genentech, Inc., South San Francisco | Kristallisierung von igf-1 |
| WO2002086105A1 (en) | 2001-04-20 | 2002-10-31 | Chiron Corporation | Delivery of polynucleotide agents to the central nervous sysstem |
| JP2005534650A (ja) | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US9408405B2 (en) * | 2003-10-03 | 2016-08-09 | Veijlen N.V. | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
| SI3045182T1 (en) * | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| BRPI0812768A2 (pt) | 2007-06-08 | 2014-12-02 | Massachusetts Inst Technology | Igf para o tratamento de síndrome de rett e transtornos sinápticos. |
| US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| US8197858B2 (en) | 2009-02-06 | 2012-06-12 | Mark John Zamoyski | Bone microenvironment modulated seizure treatments |
| DK2734634T3 (da) * | 2011-07-22 | 2019-10-21 | Univ Chicago | Igf-1 til anvendelse til behandling af migræne |
| US20190135927A1 (en) * | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
-
2020
- 2020-09-09 JP JP2022515624A patent/JP2022547948A/ja active Pending
- 2020-09-09 US US16/948,219 patent/US12324827B2/en active Active
- 2020-09-09 CA CA3153776A patent/CA3153776A1/en active Pending
- 2020-09-09 AU AU2020346186A patent/AU2020346186A1/en not_active Abandoned
- 2020-09-09 WO PCT/US2020/070511 patent/WO2021051130A1/en not_active Ceased
- 2020-09-09 EP EP20862880.0A patent/EP4027984A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503265A5 (cg-RX-API-DMAC10.html) | ||
| US20230277660A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | |
| JP2025172841A5 (cg-RX-API-DMAC10.html) | ||
| US20260132213A1 (en) | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone | |
| US20220041745A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses | |
| US20230330224A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | |
| FI4267105T3 (fi) | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä | |
| AU2019362868A1 (en) | Method of providing subcutaneous administration of anti-CD38 antibodies | |
| US20200308284A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone | |
| JP2023502398A5 (cg-RX-API-DMAC10.html) | ||
| CA2537748C (en) | Use of telmisartan for the prevention of vascular headache | |
| AU2023272504A1 (en) | Formulations for anti-insulin receptor antibody and uses thereof | |
| JP2023510854A5 (cg-RX-API-DMAC10.html) | ||
| JP2024517087A5 (cg-RX-API-DMAC10.html) | ||
| JP2024500912A5 (cg-RX-API-DMAC10.html) | ||
| JP2021522241A5 (cg-RX-API-DMAC10.html) | ||
| Silva et al. | Severe case of intrathecal baclofen withdrawal: a case report | |
| US8236323B2 (en) | Method to treat inflammation | |
| US20250353905A1 (en) | Compositions and methods for treating postural tachycardia syndrome | |
| WO2006130769A3 (en) | Methods for treatment of growth disorders | |
| JP2024501430A5 (cg-RX-API-DMAC10.html) | ||
| AU2020396455A1 (en) | Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists | |
| RU2848183C1 (ru) | Лечение болезни паркинсона | |
| US20240358726A1 (en) | Specific therapeutic medical marijuana doses for stress and pain | |
| US20230235041A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists |